Literature DB >> 9702945

Genetic testing for Gilbert's syndrome: how useful is it in determining the cause of jaundice?

A S Rudenski1, D J Halsall.   

Abstract

Gilbert's syndrome is a benign condition causing hyperbilirubinemia, which is also a symptom of liver or hemolytic disease. A genetic test may be possible for Gilbert's syndrome because an associated gene defect has been isolated. Here we present a mathematical analysis of the use of this test in excluding harmful causes of hyperbilirubinemia. The effectiveness of the test depends on a low prevalence and high penetrance of the gene defect and a low prevalence of harmful hyperbilirubinemia. If the gene defect has a 12% prevalence and 10% penetrance, then the prevalence of harmful hyperbilirubinemia needs to be <1.5% for a positive test to reduce this risk fivefold. Estimates of the prevalence of harmful hyperbilirubinemia and of the prevalence and penetrance of the Gilbert genotype are required to assess the value of the genetic test in determining a cause of hyperbilirubinemia. Until these values for prevalence and penetrance are known, genetic testing for Gilbert's syndrome cannot be recommended on a routine basis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9702945

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Prevalence of Gilbert syndrome in parents of neonates with pathologic indirect hyperbilirubinemia.

Authors:  Forough Saki; Fariba Hemmati; Mahmoud Haghighat
Journal:  Ann Saudi Med       Date:  2011 Mar-Apr       Impact factor: 1.526

2.  Gilbert's syndrome in healthy blood donors what next??

Authors:  Rajendra G Kulkarni; K B Lakshmidevi; Vidya Ronghe; U S Dinesh
Journal:  Asian J Transfus Sci       Date:  2016 Jan-Jun

3.  Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants.

Authors:  Marianne K Kringen; Armin P Piehler; Runa M Grimholt; Mimi S Opdal; Kari Bente F Haug; Petter Urdal
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.